Zobrazeno 1 - 10
of 289
pro vyhledávání: ''
Autor:
Ursa Brown-Glaberman, Hannah M. Linden, Lynn Symonds, Jennifer M. Specht, Eve T. Rodler, Isaac C. Jenkins, Xiaoyu Chai, Georgiana K. Ellis, Pavani Chalasani, Jinny Riedel, Brenda F. Kurland, Julie Gralow, Alison Stopeck, Qian Wu, Vijayakrishna V K Gadi
Publikováno v:
Clin Breast Cancer
INTRODUCTION Neoadjuvant chemotherapy is standard treatment for locally advanced (LABC) or inflammatory breast cancer (IBC). We hypothesized adding sunitinib, a tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity, to an anthracycli
Autor:
Veronica Conca, Matteo Clavarezza, Chiara Cremolini, Alessandra Boccaccino, Filippo Pietrantonio, Roberto Moretto, Cristina Granetto, Gianluca Tomasello, Alessandro Bertolini, Antonio Frassoldati, Alfredo Falcone, Mirella Giordano, Alessandro Passardi, Sara Lonardi, Anello Marcello Poma, Gianluca Masi, Gabriella Fontanini, Clara Ugolini, Giuseppe Aprile, Marco Maria Germani
Publikováno v:
European Journal of Cancer. 153:16-26
Background Recent data from the TRIBE2 study have failed to suggest a higher magnitude of benefit from upfront FOLFOXIRI/bevacizumab in patients with BRAF-mutant metastatic colorectal cancer (mCRC) as previously reported in the TRIBE study. Patients
Autor:
Richard Greil, Armin Gerger, Renate Schaberl-Moser, Martin Pichler, Dominik A. Barth, Michael Stotz, Angela Djanani, Antonia Gantschnigg, Lena Horvath, Jakob M. Riedl, Herbert Stöger, Felix Renneberg, Konstantin Schlick, Christopher Rossmann, Florian Posch, Esther Schwarzenbacher, Florian Moik
Publikováno v:
European Journal of Cancer. 151:3-13
Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no prospective randomised head-to-head comparison between these treatments has ye
Autor:
Rebeca Lozano, Gerhardt Attard, Ugo De Giorgi, Enrique Gonzalez-Billalabeitia, Giuseppe Schepisi, Isabel M. Aragón, Vincenza Conteduca, David Olmos, Daniel Wetterskog, Begoña Mellado, Nuria Romero-Laorden, Nicole Brighi, Emanuela Scarpi, Anuradha Jayaram, Cristian Lolli, Chiara Casadei, Mercedes Marín-Aguilera, Elena Castro, Giorgia Gurioli, Anna Wingate
Publikováno v:
Università degli studi di Foggia-IRIS
Background: Plasma AR status has been identified as a potential biomarker of response in metastatic castration-resistant prostate cancer (mCRPC) patients receiving docetaxel or AR-targeted therapies. However, the relevance of plasma AR in the overall
Autor:
Geraldine M. Jacobson, Gary Marano, Timothy D. Eubank, Malcolm D. Mattes, Patrick C. Ma, Mohammed Almubarak, Sijin Wen
Publikováno v:
Clin Lung Cancer
INTRODUCTION/BACKGROUND: This study assessed the safety and systemic (abscopal) response from the addition of local stereotactic body radiation therapy (SBRT) to checkpoint inhibitor (CPI) immunotherapy in patients with metastatic non-small cell lung
Autor:
Reza Sari Motlagh, Jeremy Yuen-Chun Teoh, Shin Egawa, Benjamin Pradere, Ekaterina Laukhtina, Thomas Powles, Keiichiro Mori, Victor M. Schuettfort, Marco Moschini, Francesco Soria, Shahrokh F. Shariat, Hadi Mostafaei
Publikováno v:
European Journal of Cancer. 151:35-48
Introduction Platinum-based combination chemotherapy is the standard treatment for patients with chemotherapy-eligible metastatic urothelial carcinoma (mUC). Immune-checkpoint inhibitors (ICIs) are currently assessed in this setting. This review aime
Autor:
Toshihide Yokoyama, Takashi Yokoi, Satoru Miura, Shunsuke Teraoka, Shuji Murakami, Kazushige Wakuda, Yuko Oya, Motohiro Tamiya, Atsushi Nakamura, Takaaki Tokito, Keisuke Tomii, Kenichi Yoshimura, O. Yamaguchi, Nobuyuki Yamamoto, Satoshi Watanabe, Hiroshige Yoshioka, Tetsuhiko Asao, Shoichi Itoh, D. Fujimoto, Akihiro Tamiya, Hiroshi Yokouchi, Koji Haratani
Publikováno v:
European Journal of Cancer. 150:63-72
Introduction Despite the extensive use of the combination of cytotoxic chemotherapy and programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors for cancer treatment, the incidence and characteristics of pneumonitis caused by t
Autor:
Gianluca Vullo, Mattia Falchetto Osti, Giovanna Gallo, Gerardo Salerno, Lucio Marinelli, Patrizia Cardelli, Maurizio Valeriani, Marco Alfò, Giovanna Scalabrino, Giuseppe Facondo, C. Vitiello, Ivana Russo, Barbara Campanella, Simone Burocchi, L. De Biase, V. De Sanctis
Publikováno v:
Clinical Breast Cancer. 21:e141-e149
Purpose To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal–pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay meas
Autor:
Bianca Lederer, Arndt Hartmann, Hans Ulrich Ulmer, Wolfgang D. Schmitt, Sonia L. Villegas, Jutta Engel, Frank Holms, Andreas Schneeweiss, Bruno Valentin Sinn, Claus Hanusch, Michael Untch, Karsten Weber, Valentina Nekljudova, Marion van Mackelenbergh, Frederik Marmé, Hans Tesch, Clemens Heinrichs, Christian Albig, John Hackmann, Jens Huober, Christian Jackisch, Marion Kiechle, Nicole Pfarr, Wilko Weichert, Mahdi Rezai, Simone Schrodi, Carsten Denkert, Peter A. Fasching, Peter Sinn, Sibylle Loibl
Publikováno v:
European Journal of Cancer. 148:159-170
AIM To evaluate HER2-negative breast cancer (BC) with a low hormone receptor (HR) expression, with regard to pathological complete response (pCR) and survival, in comparison to triple-negative BC (TNBC) and strong HR-positive BC. METHODS We compared
Autor:
Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, Alexander M. Menzies
Publikováno v:
European Journal of Cancer. 148:51-57
Background Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impre